Black Diamond maps new class of glioblastoma mutations

Black Diamond showed in preclinical data presented at the American Association for Cancer Research (AACR) meeting why some EGFR mutations in glioblastoma multiforme (GBM) do not respond to early generation kinase inhibitors.

The mutations occur in the extracellular domain of EGFR and are activated by disulfide-bond mediated covalent homodimerization of EGFR. Black Diamond Therapeutics Inc. (Cambridge, Mass.) dubbed these locked-dimer EGFR, or LoDi-EGFR, oncogenes...